- Home
- INMB
as 11-21-2025 3:27pm EST
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | BOCA RATON |
| Market Cap: | 49.2M | IPO Year: | 2019 |
| Target Price: | $4.30 | AVG Volume (30 days): | 363.1K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $11.64 | Next Earning Date: | 10-30-2025 |
| Revenue: | $50,000 | Revenue Growth: | 19.05% |
| Revenue Growth (this year): | 191.43% | Revenue Growth (next year): | 12299.51% |
Latest INmune Bio Inc. Common stock News
INMB Breaking Stock News: Dive into INMB Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference
Zacks
17 days ago
INmune Bio (INMB) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Yahoo Finance
22 days ago
Wall Street says tokenization will change global markets. Gold is next.
Yahoo Finance Video
22 days ago
US negotiating power is strong across the globe, except in China
Benzinga
22 days ago
DeepSeek, Qwen AI Besting ChatGPT, Grok, Gemini In AI Crypto Trading Challenge
Associated Press Finance
22 days ago
Furloughed federal workers face delays getting unemployment pay during shutdown
Simply Wall St.
22 days ago
Veralto Corporation (NYSE:VLTO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
GOBankingRates
22 days ago
The No. 1 Reason New Businesses Fail, According to a Shark Tank Investor
Compare INMB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INMB INmune Bio Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.